Candel Therapeutics (also known as Advantagene) is a biopharmaceutical company developing cancer immunotherapies. It develops Gene Mediated Cytotoxic Immunotherapy (GMCI), a platform technology designed to stimulate a patient’s immune system to naturally fight against cancer.
Type | Private | |
HQ | Arlington, VA, US | Map |
Website | candeltx.com |
Employees (est.) (Jan 2021) | 39 | (+26%) |
Cybersecurity rating | A | More |
Candel Therapeutics total Funding | $51.2 m |
Candel Therapeutics latest funding size | $22.50 m |
Time since last funding | 2 years ago |
Candel Therapeutics investors | Sands Capital Ventures, PBM Capital Group, Northpond Ventures, H7 Holdings, Level One Partners |
Candel Therapeutics has 67 Twitter Followers. The number of followers has increased 10.6% month over month and increased 34.2% quarter over quarter
73
Tweets
64
Following
67
Followers
2
Tweets last 30 days
3
Avg. likes per Tweet
100%
Tweets with engagement
How many employees does Candel Therapeutics have?
Candel Therapeutics has 39 employees.
Who are Candel Therapeutics competitors?
Competitors of Candel Therapeutics include OncoResponse, Northwest Biotherapeutics and Moleculin Biotech.
Where is Candel Therapeutics headquarters?
Candel Therapeutics headquarters is located at Rosslyn, Arlington.
Where are Candel Therapeutics offices?
Candel Therapeutics has offices in Arlington and Needham.
How many offices does Candel Therapeutics have?
Candel Therapeutics has 2 offices.
Receive alerts for 300+ data fields across thousands of companies